970 / 1835
2 Facts about ASCT salvage
•
Results of salvage ASCT
after “R”
is
worse
–
Relapse after RCHOP defines a worse prognostic group
•
CORAL
study:
–
RR
51%
v 83%
–
3y EFS
21%
v 47%
–
Relapse
< 1 year
after Rituximab 1st line: particularly poor outcome
•
Most recurrences after ASCT are in
previously involved sites
•
PARMA study results were obtained with IFRT